

# Pierre Chue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6183855/publications.pdf>

Version: 2024-02-01

40  
papers

1,018  
citations

471509

17  
h-index

434195

31  
g-index

45  
all docs

45  
docs citations

45  
times ranked

1237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reducing readmission rates for individuals discharged from acute psychiatric care in Alberta using peer and text message support: Protocol for an innovative supportive program. <i>BMC Health Services Research</i> , 2022, 22, 332.	2.2	8
2	Repetitive Transcranial Magnetic Stimulation for the Treatment of Resistant Depression: A Scoping Review. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2022, 12, 195.	2.1	9
3	Long-Term Mental Health Effects of a Devastating Wildfire Are Amplified by Sociodemographic and Clinical Antecedents in College Students. <i>Disaster Medicine and Public Health Preparedness</i> , 2021, 15, 707-717.	1.3	13
4	Prevalence Rates and Correlates of Likely Post-Traumatic Stress Disorder in Residents of Fort McMurray 6 Months After a Wildfire. <i>International Journal of Mental Health and Addiction</i> , 2021, 19, 632-650.	7.4	23
5	Text Messaging Versus Email Messaging to Support Patients With Major Depressive Disorder: Protocol for a Randomized Hybrid Type II Effectiveness-Implementation Trial. <i>JMIR Research Protocols</i> , 2021, 10, e29495.	1.0	1
6	Study of Natural Products Adverse Reactions (SONAR) in Adults with Mental Health Conditions: A Cross-Sectional Study. <i>Drug Safety</i> , 2021, 44, 999-1006.	3.2	2
7	The use of repetitive transcranial magnetic stimulation for treatment of obsessive-compulsive disorder: a scoping review. <i>Mental Illness</i> , 2021, 13, 1-13.	0.8	4
8	Long-Term Mental Health Effects of a Devastating Wildfire Are Amplified by Socio-Demographic and Clinical Antecedents in Elementary and High School Staff. <i>Frontiers in Psychiatry</i> , 2020, 11, 448.	2.6	28
9	Effectiveness of Group Cognitive Behavioral Therapy and Exercise in the Management of Major Depressive Disorder: Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e14309.	1.0	2
10	Mental Health Effects in Primary Care Patients 18 Months After a Major Wildfire in Fort McMurray: Risk Increased by Social Demographic Issues, Clinical Antecedents, and Degree of Fire Exposure. <i>Frontiers in Psychiatry</i> , 2019, 10, 683.	2.6	35
11	Prevalence Rates and Correlates of Probable Major Depressive Disorder in Residents of Fort McMurray 6 Months After a Wildfire. <i>International Journal of Mental Health and Addiction</i> , 2019, 17, 120-136.	7.4	25
12	Randomized controlled pilot trial of supportive text messaging for alcohol use disorder patients. <i>Journal of Substance Abuse Treatment</i> , 2018, 94, 74-80.	2.8	52
13	Prevalence Rates and Predictors of Generalized Anxiety Disorder Symptoms in Residents of Fort McMurray Six Months After a Wildfire. <i>Frontiers in Psychiatry</i> , 2018, 9, 345.	2.6	60
14	A review of ketamine's role in ECT and non-ECT settings. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1437-1450.	2.2	11
15	Self-reported sexual orientation among undergraduates of 10 universities in Guangzhou, China. <i>PLoS ONE</i> , 2018, 13, e0201817.	2.5	3
16	A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 109.	2.0	13
17	Study of natural health product's "drug adverse reactions (S.O.N.A.R.) in patients seeking mental health services. <i>Current Medical Research and Opinion</i> , 2016, 32, 1335-1343.	1.9	6
18	How can the new antipsychotic medications improve quality of life in patients with schizophrenia?. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1709-1711.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 777.	2.2	68
20	Glycine Reuptake Inhibitors in the Treatment of Negative Symptoms of Schizophrenia. <i>Journal of Microbiology and Biotechnology</i> , 2014, 24, 195-200.	2.1	3
21	Collaborative Care Versus Screening and Follow-up for Patients With Diabetes and Depressive Symptoms: Results of a Primary Care-Based Comparative Effectiveness Trial. <i>Diabetes Care</i> , 2014, 37, 3220-3226.	8.6	63
22	In adults with intellectual disability, discontinuation of antipsychotics is associated with reduction in weight, BMI, waist circumference and blood pressure. <i>Evidence-based Nursing</i> , 2014, 17, 89-89.	0.2	1
23	The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 259-269.	1.4	12
24	Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the Glycine Transporter 1 (GlyT1). <i>Current Pharmaceutical Design</i> , 2012, 19, 1311-1320.	1.9	27
25	A review of paliperidone palmitate. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1383-1397.	2.8	51
26	A review of olanzapine pamoate. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1661-1670.	1.8	21
27	Long-Acting Formulations of Atypical Antipsychotics. <i>CNS Drugs</i> , 2007, 21, 441-448.	5.9	52
28	Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. <i>Journal of Medical Economics</i> , 2007, 10, 427-442.	2.1	15
29	The relationship between patient satisfaction and treatment outcomes in schizophrenia. <i>Journal of Psychopharmacology</i> , 2006, 20, 38-56.	4.0	83
30	Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. <i>European Neuropsychopharmacology</i> , 2005, 15, 111-117.	0.7	166
31	Client and Community Services Satisfaction with an Assertive Community Treatment Subprogram for Inner-City Clients in Edmonton, Alberta. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 621-624.	1.9	7
32	The impact of weight gain associated with atypical antipsychotic use in schizophrenia. <i>Acta Neuropsychiatrica</i> , 2004, 16, 113-123.	2.1	10
33	Switching atypical antipsychotics: a review. <i>Acta Neuropsychiatrica</i> , 2004, 16, 301-313.	2.1	12
34	Compliance and convenience: do physicians and patients see depot medication differently?. <i>Acta Neuropsychiatrica</i> , 2004, 16, 314-318.	2.1	4
35	The Assessment and Management of Antipsychotic-Associated Metabolic Disturbances from a Psychiatric Perspective. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 200-207.	1.9	9
36	Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. <i>Bipolar Disorders</i> , 2003, 5, 62-79.	1.9	41

#	ARTICLE	IF	CITATIONS
37	Risperidone long-acting injection. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 435-446.	2.8	23
38	A review of olanzapine-associated toxicity and fatality in overdose. <i>Journal of Psychiatry and Neuroscience</i> , 2003, 28, 253-61.	2.4	34
39	Global Assessment of Functioning following Assertive Community Treatment in Edmonton, Alberta: A Longitudinal Study. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 144-148.	1.9	9
40	Hospital Outcome Measures following Assertive Community Treatment in Edmonton, Alberta. <i>Canadian Journal of Psychiatry</i> , 1999, 44, 276-279.	1.9	11